A Phase 2, Multicenter, Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Eight neurocognitive assessments will be used to assess the primary objective of evaluating the preservation of neurocognitive function over time.
One year or until the patient has evidence of neurological deterioration due to CNS metastasis, has a local recurrence, withdraws, dies, is lost to follow-up, or the study is closed.
No
United States: Food and Drug Administration
GLIA-001
NCT00525590
September 2007
March 2011
Name | Location |
---|---|
University of Iowa Hospitals and Clinics | Iowa City, Iowa 52242 |
Vanderbilt University Medical Center | Nashville, Tennessee 37232-2516 |
Temple University | Philadelphia, Pennsylvania 19140 |
University of North Carolina | Chapel Hill, North Carolina 27599 |
Cleveland Clinic | Cleveland, Ohio 44195 |
H. Lee Moffitt Cancer Center & Research Institute | Tampa, Florida 33612 |
University of California, Los Angeles | Los Angeles, California |
The University of Chicago | Chicago, Illinois 60637 |
The Ohio State University Medical Center | Columbus, Ohio 43210 |
UT Southwestern Medical Center at Dallas | Dallas, Texas 75390 |
University of South Florida | Tampa, Florida 33612 |
Methodist University Hospital | Memphis, Tennessee 38104 |
University of Arizona / University Medical Center | Tucson, Arizona 85724 |
NorthShore University HealthSystem Reseach Institute | Evanston, Illinois 60201 |
Weill Medical College Department of Neurological Surgery | New York City, New York 10021 |
Carolina Neurosurgery & Spine Associates | Charlotte, North Carolina 28204 |
Trinity Mother Frances Health System | Tyler, Texas 75702 |